“The lesson is clear: Placing marijuana products behind the counter keeps cannabis out of the hands of young people and it reduces the public’s appetite for these unregulated novel intoxicants.”
Tag: FDA
Absent cannabis descheduling, those who produce, dispense, possess, or use marijuana in compliance with state laws could still face federal prosecution for violating federal drug laws.
Rescheduling could have an outsized impact on the legal marijuana market in the nation’s capital.
“These findings highlight the need for proper regulatory oversight of cannabinoid-containing products to ensure quality assurance and deter misleading or unfounded health claims in product marketing,” the study’s authors concluded.
Perhaps most tellingly, our political opponents are also touting its significance, pledging to take whatever steps necessary to derail this proposed policy change.
“It is significant for these federal agencies, and the DEA and FDA in particular, to acknowledge publicly for the first time what many patients and advocates have known for decades: that cannabis is a safe and effective therapeutic agent for tens of millions of Americans.”
Federal health officials concluded, “The risks to the public health posed by marijuana are low compared to other drugs of abuse,” such as benzodiazepines — a Schedule IV drug, or alcohol, which is unscheduled.
“Only 18.4 percent [of the evaluated products] probably used natural hemp-derived delta-9 THC,” the study’s authors concluded.